The purpose of the study is to see whether a precision‑medicine strategy that combines these targeted drugs can improve the rate of blood‑cell recovery, known as hematologic remission, compared with standard approaches. Hematologic remission means that the abnormal blood cells are reduced to very low levels, indicating that the leukemia is under control.

Participants are randomly assigned to receive either the personalized drug combination or the standard treatment. After starting therapy, they will have regular clinic visits and simple blood tests over several months to monitor response and any side effects. The study continues for a period that allows researchers to observe how long the response lasts and whether the disease returns.

The purpose of this research is to determine if CART84 is safe to use and to find the most effective dose for treating these types of blood cancers. The treatment involves collecting immune cells from the patient, modifying them to target cancer cells, and then returning them to the patient through an intravascular infusion (delivery into a vein).

During the study, patients will receive the CART84 treatment and will be monitored for response to therapy and any side effects. After receiving CART84, some patients may proceed to receive a stem cell transplant from a matched donor. The study includes regular blood tests and bone marrow examinations to check how well the treatment is working.

The purpose of this study is to monitor patients who have already received the OC-1 cell therapy. The study will follow these patients for up to 15 years to check for any delayed side effects or adverse events. This long-term follow-up is important to ensure the safety of the treatment and to understand any potential risks that may arise over time. The study will look at various outcomes, such as the number of serious side effects, the development of new health issues, and the overall survival of patients after receiving the therapy.

During the study, researchers will also assess how long the OC-1 cells remain in the body and how they affect the patient’s health. This includes checking for the presence of the modified T-cells in the blood and evaluating their impact on the patient’s immune system. The study aims to provide valuable information about the long-term effects of this innovative treatment for patients with these challenging types of cancer.

The purpose of the study is to assess the safety of this new treatment in patients with relapsed or refractory CD1a-positive T-cell cancers. Participants in the study will receive the hCD1a-CAR T therapy through an intravenous infusion, which means the treatment is delivered directly into the bloodstream. The study will monitor patients for any side effects and evaluate how well the treatment works in controlling the cancer. Some patients may receive a placebo as part of the study to compare the effects of the new treatment.

Throughout the study, patients will have regular check-ups to assess their health and the response of their cancer to the treatment. The study aims to gather information on the remission rates, which is the period during which the cancer is under control, and overall survival, which is the length of time patients live after receiving the treatment. The study will also look at how long the modified immune cells remain active in the body. This research is important for developing new therapies for patients with these challenging types of cancer.

Participants in the study will receive Isatuximab as part of a combination chemotherapy regimen or as a single treatment, depending on their specific condition. The study will monitor how well the treatment works in reducing cancer cells and achieving remission, which means the absence of detectable cancer. The treatment will be administered through an intravenous infusion, which involves delivering the medication directly into the bloodstream through a vein.

The study will take place over a period of time, with regular visits to monitor the participants’ health and response to the treatment. The goal is to determine if Isatuximab can help patients achieve remission and improve their overall survival. The study will also track any side effects experienced by participants to ensure the treatment is safe and tolerable. This research aims to provide new insights into the treatment of T-ALL and potentially offer a new therapeutic option for patients with this challenging condition.

Participants in the study will receive Daratumumab along with the usual chemotherapy treatments. The study will monitor how well the cancer responds to this combination, particularly looking at whether the cancer cells are reduced to very low levels after the first cycle of treatment. This is known as achieving MRD-negativity, which stands for minimal residual disease negativity, indicating that very few cancer cells remain in the body.

The study will take place over several years, with regular assessments to track the progress of the treatment. Participants will receive various medications, including Cyclophosphamide, Prednisone, Dexamethasone Sodium Phosphate, Ondansetron, Methotrexate, Lenograstim, Diphenhydramine, Rasburicase, Human Fibrinogen, Pegaspargase, Allopurinol, Idarubicin Hydrochloride, Hydrocortisone, Co-trimoxazole, Vincristine Sulfate, Micafungin, Aciclovir, Chlorphenamine, Foscarnet, Levofloxacin, Folinic Acid, Ciprofloxacin, Amphotericin B, Levocarnitine, Paracetamol, Montelukast, Aprepitant, Furosemide, Mercaptopurine, Ganciclovir, Cytarabine, Granisetron, Methylprednisolone Sodium Succinate, Salbutamol, and Filgrastim, as part of their treatment plan. Some participants may receive a placebo instead of Daratumumab to compare the effects. The study aims to provide valuable insights into improving treatment for this challenging form of leukemia.

The purpose of the study is to find out if the new treatment is safe and to determine the best dose to use. The study is divided into two phases. In the first phase, the focus is on ensuring the safety of the treatment and finding the right dose. In the second phase, the study will look at how well the treatment works at the dose found in the first phase. Participants will receive the treatment and be monitored closely by healthcare professionals to see how their bodies respond.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to provide valuable information that could lead to better treatment options for those affected by this type of cancer. The study is expected to continue until 2028, with recruitment starting in 2024.